Compare Biogen Inc (BIIB) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Wipro Limited — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Wipro Limited trades at $1.85 (market cap $18.57B). The key difference: Biogen Inc is the larger of the two by market cap, and Wipro Limited pays a 10.42% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WIT | |
|---|---|---|
Market Cap | $28.34B | $18.57B |
Sector | Health | Technology |
52-Week High | $216.63 | $3.06 |
52-Week Low | $122.68 | $1.82 |
Enterprise Value | $30.62B | $14.96B |
Dividend Yield | — | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
WIT trades at $1.90, up 1.6% with bearish technical signals despite recent AI partnership announcements. The company shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B with a 14.74% margin. Recent earnings misses and weak guidance have tempered investor enthusiasm despite strong cash flow generation and AI initiatives.
WIT presents a cautious outlook with analyst consensus leaning bearish (19% buy vs 33% sell). While valuation appears reasonable (P/E 14.27) and AI partnerships offer growth potential, persistent revenue declines and execution risks in a competitive IT services market warrant careful monitoring. The stock faces near-term pressure from technical weakness and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
